ATOGEPANT | N215206 | ABBVIE INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2026-01-15 | Active | — | |
| D.N.J. | 2026-01-07 | Active | — | |
| D.N.J. | 2026-01-07 | Active | — | |
| D.N.J. | 2025-12-29 | Active | — | |
| D.N.J. | 2025-12-29 | Active | — | |
| D.N.J. | 2025-12-23 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Code | Date | Status |
|---|---|---|
| I-909 | Apr 17, 2026 | Expired |
| NCE | Sep 28, 2026 | < 1 year |
QULIPTA (atogepant) patent 8,754,096 expiration date shifted from Jul 2032 to Sep 2035, extending patent protection by approximately three years.
Old: Jul 19, 2032
New: Sep 28, 2035
Atogepant (QULIPTA) patent 8,754,096 expiration date extended from Jul 2032 to Sep 2035, reflecting a patent term adjustment grant.
Old: Jul 19, 2032
New: Sep 28, 2035
Abbvie updated the patent expiration date for listed patent 8,754,096 covering Qulipta (atogepant) from Jul 2032 to Sep 2035.
Old: Jul 19, 2032
New: Sep 28, 2035
ABBVIE listed U.S. Patent 12,622,897 for QULIPTA (atogepant) in the Orange Book.
New: New record
AbbVie added U.S. Patent 12,622,897 to the Orange Book for Qulipta (atogepant), extending patent protection for the CGRP receptor antagonist.
New: New record